Ellington Management Group LLC purchased a new stake in Davita Inc (NYSE:DVA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 14,900 shares of the company’s stock, valued at approximately $1,077,000.
Other institutional investors also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Davita in the third quarter valued at approximately $154,000. IFG Advisory LLC acquired a new stake in shares of Davita in the fourth quarter valued at approximately $205,000. Country Club Trust Company n.a. acquired a new stake in shares of Davita in the fourth quarter valued at approximately $207,000. Berkshire Asset Management LLC PA acquired a new stake in shares of Davita in the fourth quarter valued at approximately $234,000. Finally, Ferguson Wellman Capital Management Inc. acquired a new stake in shares of Davita in the fourth quarter valued at approximately $236,000. 85.83% of the stock is owned by institutional investors and hedge funds.
A number of brokerages recently weighed in on DVA. Bank of America reissued a “buy” rating and issued a $92.00 price target (up previously from $85.00) on shares of Davita in a report on Thursday, January 11th. JPMorgan Chase & Co. raised their price target on shares of Davita from $4.90 to $84.00 and gave the company a “strong-buy” rating in a report on Thursday, December 7th. Robert W. Baird reissued a “buy” rating and issued a $95.00 price target (up previously from $82.00) on shares of Davita in a report on Friday, January 12th. SunTrust Banks set a $70.00 price target on shares of Davita and gave the company a “hold” rating in a report on Thursday, December 7th. Finally, KeyCorp reaffirmed a “hold” rating on shares of Davita in a research note on Wednesday, December 6th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company. Davita presently has a consensus rating of “Hold” and an average target price of $79.30.
Davita Inc (NYSE DVA) opened at $72.46 on Monday. Davita Inc has a 52 week low of $52.51 and a 52 week high of $80.71. The stock has a market cap of $13,187.72, a P/E ratio of 21.06, a price-to-earnings-growth ratio of 1.39 and a beta of 1.03. The company has a quick ratio of 2.82, a current ratio of 2.88 and a debt-to-equity ratio of 1.87.
Davita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $0.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.02). Davita had a net margin of 4.65% and a return on equity of 12.86%. The business had revenue of $2.78 billion during the quarter, compared to the consensus estimate of $3.90 billion. During the same period in the previous year, the business posted $0.98 earnings per share. equities research analysts predict that Davita Inc will post 4.15 EPS for the current year.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.